Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value information) March 31, 2021 December 31, 2020 ...

Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. Thursday, March 6, 2025 @4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 ...

From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Nov. 17, 2023 3:01 AM ET Arcturus Therapeutics Holdings Inc. (ARCT) Stock ARCT 2 Comments 2 Likes Nelson Alves ...

Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. and Europe. The therapy has the potential to generate significant revenues ...

San Diego’s Arcturus Therapeutics received a grant of up to $10 million from a Singapore government agency to co-develop a vaccine for the deadly COVID-19 virus.Work on the vaccine will occur in ...

Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.

Arcturus Therapeutics Holdings Inc., a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare ...